A prospective, interventional assessment of psoriasis quality of life using a nonskin-specific validated instrument that allows comparison with other major medical conditions - 17/07/13
, Tejas Patel, BA b, Bonnie Koo, MD c, Thao Nguyen, MD d, Judith Hong, MD a, John Koo, MD aAbstract |
Background |
Psoriasis significantly impacts patients’ quality of life.
Objectives |
The purpose of this study was to prospectively assess the quality-of-life impact of treatment for moderate to severe plaque psoriasis by using a validated quality-of-life psychometric instrument that has been widely used in nondermatologic settings.
Methods |
In all, 32 patients with moderate to severe plaque psoriasis received 24 weeks of adalimumab treatment. Patients completed the Psychological General Well-Being (PGWB) Index, which evaluates 6 domains including anxiety and depression. The primary end point was the change in total PGWB score at weeks 12 and 24 of adalimumab treatment compared with baseline.
Results |
Statistically significant improvement in the total PGWB score was documented by week 4. By week 24, all 6 PGWB domains showed statistically significant improvement from the pretreatment baseline.
Limitations |
One limitation of this study is that the comparison between our psoriasis data and PGWB data from other major medical conditions was not conducted in a head-to-head manner. Another limitation is that we did not have a controlled (placebo) arm.
Conclusion |
Based on PGWB scores, patients with untreated psoriasis have as much impairment in psychological well-being as patients with other major medical diseases including breast cancer, coronary artery disease, congestive heart failure, and diabetes and that potent intervention improves psychological well-being to where it is comparable with that of patients with asymptomatic hypertension. A prompt intervention with an effective dermatologic treatment is not only critical, but capable of restoring the physical and psychological well-being of patients with psoriasis.
Le texte complet de cet article est disponible en PDF.Key words : adalimumab, biologics, psoriasis, Psychological General Well-Being Index, quality of life
Abbreviations used : PASI, PGWB, QoL
Plan
| Partially funded by a research grant from Abbott, Abbott Park, IL; a research grant from the Doris Duke Charitable Foundation; and a National Psoriasis Foundation Medical Dermatology grant. |
|
| Disclosure: Dr John Koo is a consultant, investigator, and speaker for Abbott. Drs Bhutani, Bonnie Koo, Nguyen, and Hong, and Mr Patel have no conflicts of interest to declare. |
Vol 69 - N° 2
P. e79-e88 - août 2013 Retour au numéro
Article précédent
- Factors associated with female pattern hair loss and its prevalence in Taiwanese women: A community-based survey
- Lin-Hui Su, Li-Sheng Chen, Hsiu-Hsi Chen
- Physician survey of dermatology quality reporting initiatives in Colorado
- Bryan T. Alvarez, Cory A. Dunnick, Robert P. Dellavalle
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?